Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - s-metolachlor; atrazine - suspension concentrate - s-metolachlor anilide/aniline-acetanilides active 290.0 g/l; atrazine triazine active 370.0 g/l - herbicide

Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - flumetsulam - water dispersible granule - flumetsulam pyrimidine-sulfonamide active 800.0 g/kg - herbicide

Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - s-metolachlor - emulsifiable concentrate - s-metolachlor anilide/aniline-acetanilides active 960.0 g/l - herbicide

Австралия - английский - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - imatinib mesilate -

Австралия - английский - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - imatinib mesilate -

Австралия - английский - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - certolizumab pegol, quantity: 200 mg - injection, solution - excipient ingredients: sodium acetate; sodium chloride; water for injections - rheumatoid arthritis cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients. ? combined with mtx in case of either an inadequate response or intolerance to previous therapy with one or more disease modifying antirheumatic drugs (dmards) or ? as monotherapy in case of a contraindication or intolerance to mtx (see section 4.2 dose and method of administration). cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray, when given in combination with mtx. cimzia in combination with mtx is indicated for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with mtx or other dmards.,psoriatic arthritis cimzia is indicated for the treatment of adult patients with active psoriatic arthritis where response to previous disease modifying antirheumatic drug therapy (dmards) has been inadequate. cimzia has been shown to improve physical function.,ankylosing spondylitis cimzia is indicated for the treatment of adult patients with active, ankylosing spondylitis who have been intolerant to or have had inadequate response to at least one nonsteroidal anti-inflammatory drug (nsaid).,non-radiographic axial spondyloarthritis cimzia is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axspa) with objective signs of inflammation as indicated by elevated c reactive protein (crp) and /or magnetic resonance imaging (mri) change, who have had an inadequate response to, or are intolerant to, nonsteroidal anti-inflammatory drugs (nsaids).,plaque psoriasis cimzia is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - ganciclovir sodium, quantity: 546 mg (equivalent: ganciclovir, qty 500 mg) - injection, powder for - excipient ingredients: - ganciclovir sxp (ganciclovir) administered as the iv infusion is indicated for the palliative treatment of confirmed sight-threatening cytomegalovirus (cmv) disease in aids and other severely immunocompromised individuals. it is indicated for the treatment of confirmed cmv pneumonitis in bone marrow transplant patients. it is also indicated for the prophylaxis of cmv infection and disease following bone marrow and solid organ transplantation in patients at risk of cmv disease.,note: ganciclovir sxp (ganciclovir) is not indicated for congenital or neonatal cmv disease; nor for the treatment of cmv infection in non-immunocompromised individuals.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 25.47 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; macrogol 400; magnesium stearate; purified talc; hypromellose; croscarmellose sodium; titanium dioxide; colloidal anhydrous silica - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder

Австралия - английский - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 12.74 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; purified talc; croscarmellose sodium; macrogol 400; hypromellose; titanium dioxide; microcrystalline cellulose; magnesium stearate - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder. treatment of obsessive-compulsive disorder

Австралия - английский - Department of Health (Therapeutic Goods Administration)

specialites septodont pty ltd - articaine hydrochloride, quantity: 88 mg; adrenaline (epinephrine) acid tartrate, quantity: 0.02 mg (equivalent: adrenaline (epinephrine), qty 0.011 mg) - injection, solution - excipient ingredients: sodium chloride; sodium metabisulfite; sodium hydroxide; water for injections - ? septanest 1:200,000 is indicated for local anaesthesia for simple dental procedures in adults, adolescents and children 4 years of age and older. ? septanest 1:200,000 is indicated only for dental procedures